NUS NU SKIN ENTERPRISES, INC.
Wholesale-Drugs, Proprietaries & Druggists' Sundries · NYSE · SEC CIK 1021561 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-15.3%
TTM net income YoY-313.7%
TTM EPS YoY-321.9%
Revenue 3-yr CAGR-12.9%
Net income 3-yr CAGR—
Margins
Gross margin67.8%
Operating margin-2.0%
Net margin-17.7%
FCF margin-2.0%
EBITDA margin1.8%
Returns
ROE-34.8%
ROA-18.6%
ROIC (approx.)-3.1%
Asset turnover1.05x
Leverage & solvency
Liabilities / assets49.7%
Debt / equity0.37x
Current ratio2.04x
Interest coverage-1.79x
Cash quality & payout
Operating cash flow / net income-0.06x
Accruals ratio-19.9%
Payout ratio—
Capex / revenue3.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $1.49B | $1.73B |
| Cost of revenue | $453.76M | $550.23M |
| Gross profit | $1.03B | $1.18B |
| R&D expense | $10.80M | $13.00M |
| SG&A expense | $432.14M | $479.04M |
| Operating income | $65.76M | -$151.59M |
| Interest expense | $13.95M | $26.41M |
| Pretax income | $196.20M | -$175.05M |
| Income tax | $35.99M | -$28.46M |
| Net income | $160.20M | -$146.59M |
| EBITDA | $118.02M | -$81.78M |
| EPS (basic) | 3.25 | -2.95 |
| EPS (diluted) | 3.18 | -2.95 |
| Weighted avg. shares (diluted) | 50.30M | 49.66M |
| Balance sheet | ||
| Cash & equivalents | $238.63M | $186.88M |
| Short-term investments | $1.21M | $11.11M |
| Receivables | $39.54M | $50.78M |
| Inventory | $178.64M | $190.24M |
| Current assets | $547.70M | $538.60M |
| PP&E, net | $377.17M | $379.60M |
| Goodwill | $83.62M | $83.62M |
| Intangibles | $42.61M | $74.28M |
| Total assets | $1.41B | $1.47B |
| Current liabilities | $263.73M | $296.61M |
| Short-term debt | $20.00M | $30.00M |
| Long-term debt | $204.19M | $363.61M |
| Total debt | $224.19M | $393.61M |
| Total liabilities | $600.07M | $817.46M |
| Shareholders' equity | $805.24M | $651.46M |
| Net debt | -$14.44M | $206.73M |
| Cash flow statement | ||
| Operating cash flow | $80.29M | $111.74M |
| Capital expenditure | $34.28M | $41.58M |
| Free cash flow | $46.01M | $70.16M |
| Investing cash flow | $170.66M | -$37.96M |
| Financing cash flow | -$202.40M | -$133.18M |
| Depreciation & amortization | $52.26M | $69.81M |
| Stock-based compensation | $24.11M | $14.82M |
| Dividends paid | $11.83M | $11.93M |
| Share buybacks | $20.04M | $0 |
Free plan shows the latest 2 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.